Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

被引：0

作者：

Strickler, J. H. ^{[1
]}

Zemla, T. ^{[2
]}

Ou, F-S. ^{[2
]}

Cercek, A. ^{[3
]}

Wu, C. ^{[4
]}

Sanchez, F. A. ^{[5
]}

Hubbard, J. ^{[6
]}

Jaszewski, B. ^{[6
]}

Bandel, L. ^{[6
]}

Schweitzer, B. ^{[6
]}

Niedzwiecki, D. ^{[7
]}

Kemeny, N. ^{[3
]}

Boland, P. M. ^{[8
]}

Ng, K. ^{[9
]}

Bekaii-Saab, T. ^{[10
]}

机构：

[1] Duke Univ, Med Ctr, Div Med Oncol, Med, Durham, NC USA

[2] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA

[3] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[4] Emory Univ, Hematol & Med Oncol, Atlanta, GA 30322 USA

[5] Aurora Canc Care, Advocate Aurora Hlth, Milwaukee, WI USA

[6] Mayo Clin, Med Oncol, Rochester, MN USA

[7] Duke Univ, Med Ctr, Biostat & Bioinformat, Durham, NC USA

[8] Roswell Pk Comprehens Canc Ctr, Internal Med, Buffalo, NY USA

[9] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[10] Mayo Clin, Ctr Canc, Med Oncol, Phoenix, AZ USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

527PD

引用

页数：1

共 50 条

[41] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
Bayo, J
Mayordomo, JI
Sanchez-Rovira, P
Perez-Carrion, R
Illaramendi, J
Flores, EG
Bueno, JMG
Vazquez, MR
Crespo, C
Palomo, AG
Huelva, HJRJ
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
[42] Trastuzumab - A review of its use in the treatment of metastatic breast cancer overexpressing HER2
McKeage, K
Perry, CM
DRUGS, 2002, 62 (01) : 209 - 243
[43] HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial.
Cercek, Andrea
Ng, Kimmie
Strickler, John H.
Siena, Salvatore
Andre, Thierry
Van Cutsem, Eric
Wu, Christina
Paulson, Andrew Scott
Hubbard, Joleen M.
Coveler, Andrew L.
Fountzilas, Christos
Kardosh, Adel
Kasi, Pashtoon Murtaza
Lenz, Heinz-Josef
Ciombor, Kristen Keon
Elez, Elena
Stecher, Michael
Cronin, Pauline
Feng, Wentao
Bekaii-Saab, Tanios S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 198 - 198
[44] Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
Calamac, M.
Minic, I.
Tomasevic, Z.
Oblakovic-Babic, J.
Serovic, K.
Djurmez, O.
Dimitrijevic, M.
Bozovic-Spasojevic, I.
BREAST, 2021, 56 : S82 - S83
[45] Ado-trastuzumab emtansine for HER2 amplified or HER2 overexpressed cancers: A phase II "basket" trial
Li, Bob T.
Zauderer, Marjorie
Chaft, Jamie
Drilon, Alexander
Eng, Juliana
Sima, Camelia
Makker, Vicky
Iyer, Gopa
Janjigian, Yelena
Hyman, David
Arcila, Maria
Baselga, Jose
Kris, Mark G.
CANCER RESEARCH, 2015, 75
[46] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
Bachmeier, Beatrice
Sperinde, Jeff
Weidler, Jodi Marie
Lie, Yolanda
Chenna, Ahmed
Winslow, John
Engel, Jutta
Schubert-Fritschle, Gabriele
Sommerhoff, Christian
Petropoulos, Christos J.
Bates, Michael Patrick
Huang, Weidong
Nerlich, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[47] Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
Mundi, P. S.
Lee, S.
Chi, D.
Bhardwaj, A.
Makower, D.
Cigler, T.
Crew, K. D.
Hershman, D. L.
Califano, A.
Silva, J.
Kalinsky, K. M.
CANCER RESEARCH, 2017, 77
[48] Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
Mosele, Fernanda
Deluche, Elise
Lusque, Amelie
Le Bescond, Loic
Filleron, Thomas
Pradat, Yoann
Ducoulombier, Agnes
Pistilli, Barbara
Bachelot, Thomas
Viret, Frederic
Levy, Christelle
Signolle, Nicolas
Alfaro, Alexia
Tran, Diep T. N.
Garberis, Ingrid Judith
Talbot, Hugues
Christodoulidis, Stergios
Vakalopoulou, Maria
Droin, Nathalie
Stourm, Aurelie
Kobayashi, Maki
Kakegawa, Tomoya
Lacroix, Ludovic
Saulnier, Patrick
Job, Bastien
Deloger, Marc
Jimenez, Marta
Mahier, Celine
Baris, Vianney
Laplante, Pierre
Kannouche, Patricia
Marty, Virginie
Lacroix-Triki, Magali
Dieras, Veronique
Andre, Fabrice
NATURE MEDICINE, 2023, 29 (08) : 2110 - +
[49] Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
Fernanda Mosele
Elise Deluche
Amelie Lusque
Loïc Le Bescond
Thomas Filleron
Yoann Pradat
Agnes Ducoulombier
Barbara Pistilli
Thomas Bachelot
Frederic Viret
Christelle Levy
Nicolas Signolle
Alexia Alfaro
Diep T. N. Tran
Ingrid Judith Garberis
Hugues Talbot
Stergios Christodoulidis
Maria Vakalopoulou
Nathalie Droin
Aurelie Stourm
Maki Kobayashi
Tomoya Kakegawa
Ludovic Lacroix
Patrick Saulnier
Bastien Job
Marc Deloger
Marta Jimenez
Celine Mahier
Vianney Baris
Pierre Laplante
Patricia Kannouche
Virginie Marty
Magali Lacroix-Triki
Veronique Diéras
Fabrice André
Nature Medicine, 2023, 29 : 2110 - 2120
[50] Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Strickler, John H.
Cercek, Andrea
Siena, Salvatore
Andre, Thierry
Ng, Kimmie
Van Cutsem, Eric
Wu, Christina
Paulson, Andrew S.
Hubbard, Joleen M.
Coveler, Andrew L.
Fountzilas, Christos
Kardosh, Adel
Kasi, Pashtoon M.
Lenz, Heinz-Josef
Ciombor, Kristen K.
Elez, Elena
Bajor, David L.
Cremolini, Chiara
Sanchez, Federico
Stecher, Michael
Feng, Wentao
Bekaii-Saab, Tanios S.
LANCET ONCOLOGY, 2023, 24 (05): : 496 - 508

← 1 2 3 4 5 →